Roth Capital Starts Merus N.V. (MRUS) at Buy

Roth Capital analyst Tony Butler initiates coverage on Merus N.V. (NASDAQ: MRUS) with a Buy rating and a price target of $20.00.

The analyst comments "We are initiating coverage of Merus, a Netherlands-based biotechnology company with a solid bispecific platform focused on developing innovative antibodies that harness the immune system to treat and potentially cure various types of cancer. Merus has several bispecifics in the clinic (HER3 x HER2, CLEC12A x CD3, and CD137 x PD-L1) that are all expected to readout during 2019."

For an analyst ratings summary and ratings history on Merus N.V. click here. For more ratings news on Merus N.V. click here.

Shares of Merus N.V. closed at $14.12 yesterday.

You May Also Be Interested In

• META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban
• Amazon.com (AMZN) PT Raised to $215 at UBS
• SEI Investments (SEIC) PT Lowered to $69 at Piper Sandler